Galecto Inc.


Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation and cancer.

Galecto was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom and Denmark. The company is currently incorporated in the U.S. and headquartered in Copenhagen, Denmark.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.